Related Experiment Video
Updated: Apr 16, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Decreased MEFV gene expression in rheumatoid arthritis patients
1Department of Medical Biology, Faculty of Medicine, Firat University, Elazig, Turkey ebruetem@gmail.com.
Abstract:
Rheumatoid arthritis (RA) is a major cause of adult chronic inflammatory arthritis and an autoimmune disease of unknown etiology in which the inflammatory pathology involves T cell activation. Genetic mutations in the Mediterranean fever (MEFV) gene, encoding pyrin, influence the severity of RA, but the underlying mechanisms are not completely understood. In this study, we investigated whether the full-length MEFV gene (MEFV-fl) and the exon 2-deleted splice isoform (MEFV-d2) expression are associated with or responsible for the clinical conditions of RA. This study include 47 patients with RA and 47 age- and gender-matched healthy controls. Quantitative real-time polymerase chain reaction analysis was performed to examine transcriptional changes in MEFV gene expression from peripheral blood samples. Reverse transcription-polymerase chain reaction of peripheral blood cells revealed the downregulation of MEFV-fl mRNA in non-treated patients compared with healthy controls and treated patients. MEFV-d2 expression was not different between groups. This is the first study to investigate the expression of MEFV transcript in RA. Deregulation of the MEFV gene is likely to result in uncontrolled inflammation as observed in RA. Therefore, downregulation of MEFV-fl may be involved in the pathogenesis of early-stage RA and treatment and may ameliorate MEFV-fl expression.
Insights
This study found that the full-length Mediterranean fever (MEFV) gene is downregulated in early-stage rheumatoid arthritis (RA) patients. This reduced MEFV-fl expression may contribute to RA pathogenesis and inflammation.
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by T cell activation and inflammation.
- The Mediterranean fever (MEFV) gene, encoding pyrin, is linked to RA severity, but its specific role in pathogenesis remains unclear.
Purpose of the Study:
- To investigate the expression of the full-length MEFV gene (MEFV-fl) and its exon 2-deleted splice isoform (MEFV-d2) in rheumatoid arthritis patients.
- To determine if MEFV gene expression is associated with RA clinical conditions.
Main Methods:
- Quantitative real-time polymerase chain reaction (RT-qPCR) was used to analyze MEFV gene expression in peripheral blood samples.
- The study included 47 RA patients and 47 age- and gender-matched healthy controls.
Main Results:
- Downregulation of MEFV-fl mRNA was observed in non-treated RA patients compared to healthy controls and treated patients.
- No significant difference in MEFV-d2 expression was found between the groups.
Conclusions:
- This is the first study to examine MEFV transcript expression in RA.
- Downregulation of MEFV-fl may play a role in the pathogenesis of early-stage RA.
- Therapeutic interventions might ameliorate MEFV-fl expression in RA patients.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
07:44Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Related Concept Videos
Master Transcription Regulators
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease I: Introduction
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies